Since its inception, the UK Cystic Fibrosis Infection Biorepository (UKCFIB) has made significant strides in accelerating drug and diagnostic discovery efforts for cystic fibrosis (CF) lung infections. By uniting eight CF centres and associated laboratories across the UK, the biorepository has streamlined access to samples and expertise, including novel sample types from people living with CF.
The biorepository has brought together collections from multiple centres, providing access to more than 34,000 samples, supported over 20 innovators, and fostered important collaborations. It has also supported the development of bespoke strain collections and panels, provided essential guidance to the sector, and reduced time-to-sample, accelerating development timelines.
With its globally accessible collection of enriched samples from CF and non-CF sources, the biorepository serves as a key resource, supporting innovators in developing new therapies and diagnostic tools to improve the lives of people living with CF and other chronic lung infections.
Now, as we look to the future, the biorepository remains committed to enabling access to high-quality samples, data, and collaborative expertise to support researchers in advancing innovation in CF and beyond.
Read the report below or click here if it doesn’t display to see a full page view.
